May 20th 2024
During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Chemotherapy Plus Inotuzuamb Ozogamicin Elicits Promising Responses in B-Cell ALL
July 21st 2023Utilizing the combination of inotuzuamb ozogamicin and low intensity chemotherapy, with or without blinatumoamab, showed promising results, but also an increase of patient deaths during remission.
Read More
Assessing and Monitoring Manifestations of Chronic GVHD
July 18th 2023Catherine J. Lee, MD, MS, associate professor of medicine in the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington, led a live virtual discussion on how to treat patients with chronic graft-vs-host disease (GVHD) and how best to assess the extent of their disease.
Read More
NCCN Update Aids Clinicians in Managing Methotrexate Toxicities
June 27th 2023Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.
Read More
NDA Submitted to the FDA for Imetelstat in R/R Myelodysplastic Syndrome
June 21st 2023Following positive data from the phase 3 IMerge study of imetelstat, the FDA has received a new drug submission for the agent for the treatment of patients with relapsed or refractory myelodysplastic syndrome.
Read More
Roxadustat Misses Efficacy End Point in Phase 3 MDS Study
May 12th 2023The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.
Read More
Mosunetuzumab Maintains Efficacy/Survival Benefit in Elderly Patients With DLBCL
May 5th 2023In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.
Read More
FDA Accepts sBLA of Luspatercept for Anemia in Patients With Lower-Risk MDS
May 1st 2023Findings from the COMMANDS study in which luspatercept showed statistically significant and clinically meaningful improvements for patients with low-risk myelodysplastic syndrome, the FDA has set a target action date of August 28, 2023.
Read More